Navigation Links
Novel mechanism found that may boost impaired function of leukemia protein
Date:2/29/2008

NEW YORK, February 29, 2008 A new study led by researchers at Memorial Sloan-Kettering Cancer Center (MSKCC) reports on a novel mechanism that can enhance the function of a protein that is frequently impaired in patients with acute forms of leukemia. The protein, called AML1, plays a critical role in the development of the blood system and in the production of platelets and immune cells. The findings are published in the March 1, 2008, issue of Genes & Development.

According to the study, investigators identified the methyltransferase enzyme that controls the activity of the normal AML1 protein also called RUNX1 demonstrating its ability to regulate the function of transcription factors, proteins that control cell fate by turning genes on or off. The researchers found that the cellular pathways that regulate the activity of the normal AML1 protein through a process called arginine methylation cannot similarly regulate the activity of AML1-ETO, a protein associated with causing acute leukemia.

Methylation is the process by which methyltransferases catalyze the attachment of a methyl group to DNA or protein in order to regulate gene expression or protein function. Demethylase enzymes that remove methyl groups from proteins have only recently been discovered.

By manipulating the activity of these enzymes, it may be possible to promote the activity of the normal protein, and thereby lessen the impact of the protein that promotes leukemia, said the studys senior author Stephen D. Nimer, MD, Chief of the Hematology Service at MSKCC. We are just beginning to explore whether we can tilt the balance toward a normally functioning AML1 protein in leukemic cells and either trigger their death or their reversion to normal behavior.

There are currently no available drugs that target protein methylation, although two drugs that target DNA methylation are FDA approved for treating patients with myelodysplastic syndromes.

We hope to utilize these new findings to help develop and ultimately test new treatment strategies for patients with either myeloid or lymphoid types of acute leukemia, said the studys first author, Xinyang Zhao, a member of Dr. Nimers laboratory.

Dr. Nimer has been researching the AML1-ETO protein at MSKCC since 1993. He and his colleagues first demonstrated in 1995 that AML1-ETO functions as a transcriptional repressor and dominantly inhibits AML1 function.


'/>"/>

Contact: Esther Napolitano
napolite@mskcc.org
212-639-3139
Memorial Sloan-Kettering Cancer Center
Source:Eurekalert

Related medicine news :

1. Novel method to reveal drug targets
2. Novel link between excessive nutrient levels and insulin resistance
3. Novel organic metal hybrids that will revolutionize materials science and chemical engineering
4. Novel mathematical model predicts new wave of drug-resistant HIV infections in San Francisco
5. Novel approach strips staph of virulence
6. UCSD research team identifies novel anticancer drug from the sea
7. Novel compound may lessen heart attack damage
8. Novel molecules developed at UB can boost vaccine potency
9. Novel small molecule therapy shows benefit for anemic patients via hydration of red blood cells
10. Novel vaccine concept developed by scientists at the Wistar Institute
11. Tibotec Pharmaceuticals a Respectful Partner to HIV Community in Pricing of Novel New HIV NNRTI, INTELENCE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... Agoura Hills, CA (PRWEB) , ... January 18, ... ... risk of dental problems ranging from gum disease to enamel erosion, and those ... from the Massachusetts Department of Public Health, many pregnant women are failing to ...
(Date:1/17/2017)... ... January 17, 2017 , ... Anesthesia Progress ... dentists to choose the best drug option for each patient. Dentists have several general ... better overall outcomes. , Researchers from the Tokyo Dental College in Tokyo, Japan wanted ...
(Date:1/17/2017)... ... ... For breast cancer clinicians and researchers who were unable to attend the 2016 ... and analysis of its highlights, a novel half-day, complimentary meeting—the 14th Annual Best of ... 4, 2017 in Chicago. Chaired by Kathy S. Albain, MD, FACP, FASCO from the ...
(Date:1/17/2017)... ... ... SunView Software’s Service Smart Technology has been selected as a finalist for ... year, Pink Elephant recognizes a new product or service developed by an IT services ... opportunity. The award highlights original innovations that were released in 2016, either as a ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... century approach to infusing high speed technology into the fabric of an entire ... the advancement of healthcare and wellness in a yet-to-be-named, health focused campus. Leading ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... , Jan. 18, 2017 Safe Rx ... of pharmacies based in Loveland, Colorado ... Vials (LPVs) in selected Good Day locations.     ... a cost-effective alternative for secure storage," said Milton ... less than the price of a cup of coffee, ...
(Date:1/18/2017)... , Jan. 18, 2017 Invetech, ... for cell and advanced therapies , has announced ... biopharmaceutical company developing "tumor starvation" treatments for acute ... needs. Under the agreement, Invetech will develop systems ... on Erytech,s proprietary ERYCAPS technology platform, which uses ...
(Date:1/18/2017)... , January 18, 2017 After ... people regarding the use of cannabis both for medical and ... are more Americans open to the use of cannabis, but ... sectors. According to Arcview Market Research, the North American legal ... 30% from the previous year. The research projects sales will ...
Breaking Medicine Technology: